John J. Miller, MD:Sandy, what are some of the health inequities or social determinants of health that might limit the optimal treatment of schizophrenia?
Sandy Dimiterchik: This month [July] is Minority Mental Health [Awareness] Month. It’s a [good] time to look at the barriers to care that people who are minoritized face. There’s a lack of awareness, there’s a lack of access to quality care. I’ve experienced different systems, so to speak. I had a kind psychiatrist who only charged me $25, and he got me all my medications through samples for a couple of years. When I found myself at a homeless shelter or assisted living facility, there was a doctor who did a similar thing for the residents. They were so excited when they met me because I was taking atypical antipsychotic drugs, and they were still on the older versions. They went to the doctor and said, “Hey, Sandy’s taking this. What about us?” I’ve also experienced working through the county. That can be difficult because sometimes they do first come, first served, or it might take a while to get your appointment. I’ve also had private insurance, which of course private insurance was the best quality for me.
John J. Miller, MD: Thank you for sharing that.
Caroline P. Carney, MD, MSc, FAPA, FAPM, CPHQ: Dr Miller, could I jump in on that?
John J. Miller, MD: Please, Dr Carney.
Caroline P. Carney, MD, MSc, FAPA, FAPM, CPHQ: I think one of the things we see building, Sandy, on what you’re saying in terms of social determinants, often is related to the negative symptoms and the cognitive symptoms an individual has in terms of their ability to be able to ultimately navigate life, depending on the severity of schizophrenia. [This includes the ability] to pay bills, to keep the heat on, to be able to have enough executive planning to go to the grocery store, bring home food, make meals, to do the tasks that the disease itself influences the ability to do. And what ends up happening is a compounded effect. There is another issue in terms of the positive symptoms that may be frightening to family members or social supports. Individuals tend to lose that critical part of living in terms of having that social support and community. And that as we know is a huge predictor of how well a person does over time.
John J. Miller, MD: Thank you for that.
Nev Jones, PhD: Just a few things I would add there as well. One, in terms of the big picture, what we know from the psychiatric epidemiology literature is that many major determinants of health, including poverty, childhood adversity, and neighborhood adversity, are among the strongest predictors of developing psychosis. Just the onset of psychosis itself is heavily shaped by underlying social and structural determinants. Then those same determinants proceed to influence every aspect of access to treatment and services, the quality of services once people are able to access them in some way, as well as long-term outcomes. We see ethno-racial disparities at every single one of those junctures.
In the United States, African Americans are 3 to 4 times as likely to be diagnosed with schizophrenia and experience poor services, poor access, and poor outcomes along the pipeline. I also think it’s really important to emphasize that some of that has to do with experiences of services. We know that during initial pathways to care, members of minoritized ethno-racial groups are much more likely to experience coercion, seclusion, and restraint in inpatient environments, which in turn impacts treatment engagement for very good reasons. People who have had bad experiences with the system don’t necessarily want to continue. I think one of the biggest challenges probably of the times we’re in, in 2023, in light of Black Lives Matter, is seriously engaging with these disparities as they play out across every aspect of what those of us working in psychosis services or community mental health as well as on the private side are facing here.
Transcript edited for clarity.
Social Determinants of Health Limiting Optimal Treatment for Schizophrenia
Social determinants of health impacting the treatment landscape for schizophrenia are discussed.
EP: 1.Schizophrenia Disease State Overview
EP: 2.Examining Cognitive Impairment Associated with Schizophrenia
EP: 3.Social Determinants of Health Limiting Optimal Treatment for Schizophrenia
EP: 4.Assessing Cognitive Function in Patients with Schizophrenia
EP: 5.Barriers to Appropriate Care for Patients Diagnosed with Schizophrenia
EP: 6.Factors Influencing Disease Course of Schizophrenia
EP: 7.Current Standards of Care in Schizophrenia
EP: 8.Selecting Appropriate Schizophrenia Treatment
EP: 9.Utilizing Cognitive Behavioral Therapy (CBT)
EP: 10.Evaluating Schizophrenia Treatment Effectiveness
EP: 11.Payer Strategies to Manage Costs Associated with Treating Schizophrenia
EP: 12.Evolution of Schizophrenia Treatment Shaped by the COVID-19 Pandemic
EP: 13.Pipeline Treatments for Schizophrenia
EP: 14.Unmet Needs Surrounding Schizophrenia Treatment
John J. Miller, MD:Sandy, what are some of the health inequities or social determinants of health that might limit the optimal treatment of schizophrenia?
Sandy Dimiterchik: This month [July] is Minority Mental Health [Awareness] Month. It’s a [good] time to look at the barriers to care that people who are minoritized face. There’s a lack of awareness, there’s a lack of access to quality care. I’ve experienced different systems, so to speak. I had a kind psychiatrist who only charged me $25, and he got me all my medications through samples for a couple of years. When I found myself at a homeless shelter or assisted living facility, there was a doctor who did a similar thing for the residents. They were so excited when they met me because I was taking atypical antipsychotic drugs, and they were still on the older versions. They went to the doctor and said, “Hey, Sandy’s taking this. What about us?” I’ve also experienced working through the county. That can be difficult because sometimes they do first come, first served, or it might take a while to get your appointment. I’ve also had private insurance, which of course private insurance was the best quality for me.
John J. Miller, MD: Thank you for sharing that.
Caroline P. Carney, MD, MSc, FAPA, FAPM, CPHQ: Dr Miller, could I jump in on that?
John J. Miller, MD: Please, Dr Carney.
Caroline P. Carney, MD, MSc, FAPA, FAPM, CPHQ: I think one of the things we see building, Sandy, on what you’re saying in terms of social determinants, often is related to the negative symptoms and the cognitive symptoms an individual has in terms of their ability to be able to ultimately navigate life, depending on the severity of schizophrenia. [This includes the ability] to pay bills, to keep the heat on, to be able to have enough executive planning to go to the grocery store, bring home food, make meals, to do the tasks that the disease itself influences the ability to do. And what ends up happening is a compounded effect. There is another issue in terms of the positive symptoms that may be frightening to family members or social supports. Individuals tend to lose that critical part of living in terms of having that social support and community. And that as we know is a huge predictor of how well a person does over time.
John J. Miller, MD: Thank you for that.
Nev Jones, PhD: Just a few things I would add there as well. One, in terms of the big picture, what we know from the psychiatric epidemiology literature is that many major determinants of health, including poverty, childhood adversity, and neighborhood adversity, are among the strongest predictors of developing psychosis. Just the onset of psychosis itself is heavily shaped by underlying social and structural determinants. Then those same determinants proceed to influence every aspect of access to treatment and services, the quality of services once people are able to access them in some way, as well as long-term outcomes. We see ethno-racial disparities at every single one of those junctures.
In the United States, African Americans are 3 to 4 times as likely to be diagnosed with schizophrenia and experience poor services, poor access, and poor outcomes along the pipeline. I also think it’s really important to emphasize that some of that has to do with experiences of services. We know that during initial pathways to care, members of minoritized ethno-racial groups are much more likely to experience coercion, seclusion, and restraint in inpatient environments, which in turn impacts treatment engagement for very good reasons. People who have had bad experiences with the system don’t necessarily want to continue. I think one of the biggest challenges probably of the times we’re in, in 2023, in light of Black Lives Matter, is seriously engaging with these disparities as they play out across every aspect of what those of us working in psychosis services or community mental health as well as on the private side are facing here.
Transcript edited for clarity.
Risk Assessments of Drug-Related Problems for Cardiac Surgery Patients
May 10th 2024Risk assessments of drug-related problems for cardiac surgery patients can be conducted by implementing a framework for patient safety.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Updates on Adagrasib in CRC and the Importance of Genomic Testing With Dr Jun Gong
December 21st 2023Jun Gong, MD, of Cedars-Sinai Medical Center, discusses the latest data on adagrasib in colorectal cancer, the importance of conducting genomic testing, and more.
Listen
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer
May 9th 2024Pembrolizumab has existing indications in endometrial cancer.
Read More
Risk Assessments of Drug-Related Problems for Cardiac Surgery Patients
May 10th 2024Risk assessments of drug-related problems for cardiac surgery patients can be conducted by implementing a framework for patient safety.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Updates on Adagrasib in CRC and the Importance of Genomic Testing With Dr Jun Gong
December 21st 2023Jun Gong, MD, of Cedars-Sinai Medical Center, discusses the latest data on adagrasib in colorectal cancer, the importance of conducting genomic testing, and more.
Listen
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer
May 9th 2024Pembrolizumab has existing indications in endometrial cancer.
Read More